Cordlife Group Limited · SGX:P8A
Cordlife — H1 2022 Earnings Presentation
17 slides from Cordlife's earnings presentation, Nov 16, 2022
Slide 1: 1H2022 Results Presentation
1H2022 Results Presentation 1
Slide 2: Disclaimer
Disclaimer This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Cordlife Group Limited (“Cordlife”) in Singapore or any other jurisdiction nor shall it or any part of it form the basi
Slide 3: Content
Content 1 Results Summary 2 Financial Highlights 3 Outlook & Growth Strategies 3
Slide 4: 1H2022 Results Summary
1H2022 Results Summary REVENUE GROSS PROFIT GP MARGIN S$26.2 million S$17.6 million 67.0% (4.0)% y-o-y (6.5)% y-o-y -1.8 pp y-o-y OPERATING NET CASH1 NET PROFIT NET PROFIT MARGIN S$1.9 million 6.2% S$78.8 million (24.1)% y-o-y -1.9 pp y-o-y (S$0.14) million from 31 Dec 2021 1. Includes cash and cash
Slide 5: Financial Highlights
Financial Highlights cordlife a
Slide 6: Financials – Revenue
Financials – Revenue S$ mil 80 69.5 69.8 70 60 59.0 59.0 56.7 50 40 30 27.3 26.2 20 10 0 FY2017 12M2018 FY2019 FY2020 FY2021 1H2021 1H2022 – The Group’s 1H2022 revenue decreased 4.0% yoy to S$26.2 million. – This was mainly due to a decrease in the number of new samples processed and stored in Singa
Slide 7: Financials – Quarter-on-quarter Revenue
Financials – Quarter-on-quarter Revenue S$ mil 20 17.7 18.0 17.7 18 16.5 16.6 15 14.6 14.8 14.6 14.0 13.9 13.9 13.4 13.0 13.2 13 10 8 5 3 0 1Q2019 2Q2019 3Q2019 4Q2019 1Q2020 2Q2020 3Q2020 4Q2020 1Q2021 2Q2021 3Q2021 4Q2021 1Q2022 2Q2022 7
Slide 8: Financials – Gross Profit
Financials – Gross Profit S$ mil 90 68.7% 68.0% 69.7% 68.8% 66.8% 67.0% 64.2% 80 70 60 50 46.5 47.9 37.8 40.1 39.5 40 30 20 18.8 17.6 10 0 FY2017 12M2018 FY2019 FY2020 FY2021 1H2021 1H2022 Gross profit Gross profit Margin 8
Slide 9: Financials – Operating profit after tax
Financials – Operating profit after tax S$ mil 10 9 10.2% 9.7% 8.4% 8.1% 8 6.2% 0.9% 1.7% 7 5.8 6.0 6 5.5 5 4 3 2.2 2 1.6 1.2 1 0.5 0 FY2017 12M2018 FY2019 FY2020 FY2021 1H2021 1H2022 Operating profit after tax Net operating profit margin 9
Slide 10: Financials – Balance Sheet
Financials – Balance Sheet S$’ mil As at 30 Jun 2022 As at 31 Dec 2021 Net Assets 134.6 136.7 Borrowings — — Gearing1 (%) — — Cash & Cash Equivalents2, Fixed Deposits and Short-term and Long- 78.8 79.0 term Investments Net Asset Value Per Share (SG cents) 52.60 53.54 1: Total Borrowings/Total Equity
Slide 11: Financials – Cash Flow
Financials – Cash Flow For the six months For the six months S$’ mil ended 30 Jun 2022 ended 30 Jun 2021 Net cash generated from operating activities 4.1 4.4 Net cash used in investing activities1 (3.4) (4.6) Net cash used in financing activities (2.3) (6.3) Net decrease in cash and cash equivalents
Slide 12: Outlook & Growth Strategies
Outlook & Growth Strategies 12
Slide 13: Outlook
Outlook Business Outlook – The Group managed to achieve stability in revenue over the past quarters despite the spike in COVID-19 cases in the Singapore market, with the diagnostics services continuing on a positive growth trajectory. – The inflationary pressures experienced by the global macroecono
Slide 14: Growth Strategies
Growth Strategies Increase penetration rate &/or market share Increase product scope Organic Open new markets Growth Facilitate deve m cell e¢ Create new engines of growth Mergers& Acquisitions Eamings accretive
Slide 15: Growth Strategies
cordlife en Increase penetration rate &/or market share Increase product scope Organic Open new markets Growth Growth Strategies Facilitate development of stem cell ecosystem Create new engines of growth
Slide 16: Growth Strategies – Mergers & Acquisitions
cordlife en Growth Mergers& Acquisitions Strategies
Slide 17: Thank you
Thank you 17